BioLineRx(US:BLRX) Prnewswire·2025-05-27 11:00Core Insights - BioLineRx Ltd. reported continued progress in evaluating assets for potential in-licensing and development in oncology and rare diseases, with optimism for a meaningful transaction in 2025 [2][5] - The company provided updates on the performance of APHEXDA under Ayrmid's stewardship, generating $1.4 million in sales and $0.3 million in royalty revenues for Q1 2025 [3][5] - The ongoing CheMo4METPANC Phase 2b trial of motixafortide in pancreatic ductal adenocarcinoma (PDAC) is set to present new data at the 2025 ASCO Annual Meeting [1][6] Financial Updates - For the quarter ended March 31, 2025, total revenues were $0.3 million, a significant decrease from $6.9 million in Q1 2024, primarily due to the one-time revenues from the out-licensing transaction in 2024 [9][16] - Research and development expenses decreased by 34.9% to $1.6 million compared to $2.5 million in Q1 2024, attributed to lower expenses related to motixafortide and reduced headcount [9][16] - Net income for Q1 2025 was $5.1 million, a substantial increase from a net loss of $0.7 million in Q1 2024 [9][16] Clinical Updates - The CheMo4METPANC Phase 2b trial has activated additional sites to enhance patient recruitment, with full enrollment expected by 2027 [6] - Key highlights from the trial include significant patient responses, with one patient achieving complete resolution of liver lesions and another showing a sustained partial response [6] - Enrollment is ongoing for a Phase 1 trial evaluating motixafortide for mobilization of CD34+ hematopoietic stem cells in sickle cell disease, sponsored by St. Jude Children's Research Hospital [9] Corporate Developments - The company completed financing in January 2025, raising gross proceeds of $10 million and successfully reduced operating expenses by over 70% [5] - BioLineRx's cash runway is reaffirmed through the second half of 2026, with cash and cash equivalents totaling $26.4 million as of March 31, 2025 [9][19]